Melanotan I (Afamelanotide) Research Guide Ireland

Overview

Melanotan I, known by its pharmaceutical name Afamelanotide, is an alpha-melanocyte-stimulating hormone (alpha-MSH) analogue that acts as a selective agonist at the melanocortin-1 receptor (MC1R), expressed on melanocytes. Unlike many peptides discussed in a research context, Afamelanotide has genuine, licensed medicinal status: it is approved by the European Medicines Agency (since 2014, under the brand name Scenesse) and by the US FDA (since 2019) for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe light-induced skin pain and damage. It is important to distinguish two very different things that both get called "Melanotan I." The approved product, Scenesse, is administered as a subcutaneous implant by a healthcare professional in a specialist clinical setting, under strict regulatory control. Separately, unregulated injectable "Melanotan I" products sold online or through grey-market channels are not the same regulated pharmaceutical product — they carry a different (and largely unverified) risk, purity and quality profile, and are not licensed by the HPRA or any equivalent regulator for use in Ireland. This guide distinguishes the approved medicinal use of afamelanotide (Scenesse implant, for EPP) from the unregulated research/off-label use of injectable Melanotan I throughout.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✔ (EMA 2014 & FDA 2019 — Scenesse implant, EPP only. Unregulated injectable "Melanotan I" products are not the licensed product.)

Mechanism of Action

Afamelanotide (Melanotan I) is a selective agonist at the melanocortin-1 receptor (MC1R) expressed on the surface of melanocytes in the skin. Binding of the peptide to MC1R stimulates intracellular signalling that upregulates tyrosinase activity and shifts melanin synthesis toward eumelanin, the darker, more photoprotective form of skin pigment, as opposed to the lighter, less protective pheomelanin. This increase in eumelanin content provides a physical barrier that reduces the penetration of UV and visible light into the skin, which is the mechanistic basis for Scenesse's approved use in erythropoietic protoporphyria: by increasing baseline skin pigmentation, afamelanotide reduces the severity of phototoxic reactions triggered by light exposure in EPP patients, who otherwise cannot tolerate normal levels of sunlight or even some indoor lighting.

Research Areas & Reported Effects

Erythropoietic Protoporphyria Photoprotection (Approved Indication)

The core, regulator-approved application of afamelanotide is photoprotection in EPP. Phase 3 clinical trial data, most notably the landmark study by Langendonk JG and colleagues published in the New England Journal of Medicine, demonstrated meaningful increases in pain-free time in sunlight for EPP patients receiving afamelanotide implants compared to placebo.

Vitiligo Repigmentation Research

Afamelanotide has been studied, often in combination with narrowband UVB (NB-UVB) phototherapy, for its potential to enhance repigmentation in patients with vitiligo. Research led by groups including Grimes PE and colleagues has examined combined afamelanotide plus NB-UVB protocols against NB-UVB alone.

General Photoprotection and Skin Cancer Prevention Research

Beyond EPP, afamelanotide has been studied in populations at elevated skin cancer risk, including organ transplant recipients, as a potential adjunct for reducing UV-induced DNA damage. Pilot work by Harms J and colleagues explored this preventive photoprotection angle in immunosuppressed populations.

Cosmetic Tanning and Off-Label/Grey-Market Use

Historically, unregulated injectable Melanotan I products have been marketed and used off-label for cosmetic tanning purposes without medical supervision. This use sits entirely outside the licensed indication and dosing form (the Scenesse implant) and outside any regulatory oversight, and is not supported by the clinical trial evidence base underpinning the approved product.

Research Data Summary

Study / Model	Reported Effect
Langendonk JG et al. 2015 (NEJM)	Afamelanotide implants significantly increased daily pain-free time in direct sunlight for EPP patients versus placebo across two randomised Phase 3 trials.
Biolcati G et al. long-term real-world data	Sustained improvement in phototoxic reaction frequency and quality of life in EPP patients receiving repeated afamelanotide implants over extended follow-up periods.
Lim HW et al. phototoxicity studies	Reported reduction in phototoxic reaction severity and frequency associated with increased skin eumelanin content following afamelanotide administration.
Grimes PE et al. vitiligo study	Afamelanotide combined with NB-UVB produced greater repigmentation of vitiligo lesions compared to NB-UVB monotherapy in a randomised trial.
Harms J et al. transplant recipient pilot study	Preliminary evidence of reduced UV-induced skin damage markers in organ transplant recipients receiving afamelanotide, in a small pilot cohort.

Stack Combinations Studied

• Afamelanotide + narrowband UVB (NB-UVB) phototherapy → Research rationale: Investigated in vitiligo repigmentation trials, where afamelanotide-driven melanocyte stimulation is combined with UVB-driven melanocyte activation to study additive repigmentation effects versus NB-UVB alone.
• Afamelanotide + routine photoprotection measures (sunscreen, protective clothing) → Research rationale: Studied as a combined approach in EPP management research, positioning afamelanotide as an adjunct to, not a replacement for, standard physical photoprotection.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Approved EPP Implant Protocol (Scenesse)	16 mg subcutaneous implant	Sustained release over approximately 2 months per implant	Every 2 months, clinic-administered	Licensed EPP photoprotection regimen, administered by a healthcare professional.
Vitiligo Research Protocol	16 mg implant, combined with NB-UVB sessions	Several months (research trial duration)	Monthly implant, twice-weekly phototherapy	Repigmentation trials in vitiligo research cohorts.
Early Photoprotection Pilot Protocol	Lower research doses in early Phase 1/2 studies	Weeks (early trial duration)	Variable, per trial design	Early dose-finding and tolerability research ahead of the approved implant regimen.

Observed Side Effects in Research

• Nausea
• Headache
• Fatigue
• Implant site reactions/nodules
• Mild darkening of naevi (moles), clinically monitored with repeated use
• Flushing

Skin surveillance is recommended with repeated afamelanotide use given the observed effect on naevi pigmentation; this is actively monitored in both the approved clinical use and the research literature.

Compound Data

CAS Number

75921-69-6

Molecular Formula

C₆₃H₉₃N₁₇O₁₄

Molecular Weight

Approximately 1297.5 g/mol

Half-Life

Plasma half-life of a few hours for the free peptide; the Scenesse implant is designed for sustained release over approximately 2 months

Synonyms

Afamelanotide, Melanotan I, [Nle4-D-Phe7]-alpha-MSH (related but distinct from NDP-MSH), Scenesse (brand name), CUV1647

Research Classification

Melanocortin-1 receptor (MC1R) agonist, alpha-MSH analogue

Scientific References

• [Langendonk JG et al. 2015] — Afamelanotide for erythropoietic protoporphyria. — New England Journal of Medicine — [Human RCT]
• [Biolcati G et al. 2015] — Long-term safety and efficacy of afamelanotide in patients with erythropoietic protoporphyria. — British Journal of Dermatology — [Observational / Human]
• [Harms J et al. 2009] — Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. — Photodermatology, Photoimmunology & Photomedicine-adjacent research — [Pilot Human Study]
• [Grimes PE et al. 2013] — Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo. — JAMA Dermatology — [Human RCT]
• [Fabrikant J et al.] — Review of afamelanotide mechanisms and clinical pharmacology. — Dermatology review literature — [Pharmacology Review]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*